GPP
AVTX icon

Great Point Partners’s Avalo Therapeutics AVTX Stock Holding History

Great Point Partners’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.86M Hold
124,666
– – 0.43% 39
2025
Q4 		$2.26M Buy
+124,666
New +$2.1M 0.73% 28
2023
Q2 		– Sell
-1,978
Closed -$831K – 42
2023
Q1 		$831K Buy
+1,978
New +$1.56M 0.16% 42

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Great Point Partners's AVTX Position: Q1 2026 in Review

Great Point Partners held its Avalo Therapeutics (AVTX) position steady in Q1 2026 at 124,666 shares worth $1.86M. The position accounts for 0.43% of the portfolio, ranked #39.

Great Point Partners first reported a position in AVTX in Q1 2023 and has held it in 3 quarters since. The position peaked at $2.26M in Q4 2025. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Great Point Partners held 124,666 shares of Avalo Therapeutics worth $1.86M as of Q1 2026.
  • Great Point Partners left its Avalo Therapeutics share count unchanged in Q1 2026.
  • Avalo Therapeutics made up 0.43% of Great Point Partners's portfolio in Q1 2026, its #39 holding.
  • Great Point Partners first reported a position in Avalo Therapeutics in Q1 2023 and has held it in 3 quarters since.
  • Great Point Partners's Avalo Therapeutics position peaked at $2.26M in Q4 2025.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.